Hecate OncoSolutions is a Houston based startup with the goal to translate basic science findings into effective treatments by developing channels and collaborations to expedite this complex route for promising antineoplastic agents. “Macar-A” (Schweinfurthin-A), is a suitable therapeutic solution for benign and malignant tumors developed in patients with NF1. There are more than 90,000 patients currently living with Neurofibromatosis Type I (NF1) in the USA. NF1 is a genetic disease caused by the malfunction of neurofibromin, a regulatory protein. Most of the patients develop benign tumors that can be removed by surgery. However, 1 in 20 will develop malignant tumors, such as malignant peripheral nerve sheath tumors (MPNST) and, optic and malignant gliomas. MPNST do not respond to standard chemotherapy or radiation therapy and current treatment options do not improve the 5-year survival beyond 50%. Current clinical trials for these tumors include drugs that also affect normal cells...
Hecate OncoSolutions is a Houston based startup with the goal to translate basic science findings into effective treatments by developing channels and collaborations to expedite this complex route for promising antineoplastic agents. “Macar-A” (Schweinfurthin-A), is a suitable therapeutic solution for benign and malignant tumors developed in patients with NF1. There are more than 90,000 patients currently living with Neurofibromatosis Type I (NF1) in the USA. NF1 is a genetic disease caused by the malfunction of neurofibromin, a regulatory protein. Most of the patients develop benign tumors that can be removed by surgery. However, 1 in 20 will develop malignant tumors, such as malignant peripheral nerve sheath tumors (MPNST) and, optic and malignant gliomas. MPNST do not respond to standard chemotherapy or radiation therapy and current treatment options do not improve the 5-year survival beyond 50%. Current clinical trials for these tumors include drugs that also affect normal cells causing several side effects. Macar-A is a small molecule that affects only NF1 mutant cancer cells by disrupting their cytoskeleton without affecting normal cells. Currently Macar-A is in early experimental phase. We will be licensing the technology from National Institutes of Health (US Patent 8,686,016, Issued April 01, 2014). Our first milestone is to complete pre-clinical experiments by 2018 with an initial investment of $1 million and the collaboration of academic research laboratories. In 2019 we will initiate the Phase I clinical trial for the FDA approval process with an orphan disease indication for malignant glioma and MPNST; this require an investment of $1.5 million. Once Macar-A clears Phase 1 and 2 clinical trials we will introduce it as a complementary therapy to surgery for invasive neurofirbomas and other NF1 related cancers. Based on our conservative estimates, we project that Macar-A has a $112.5M annual revenue opportunity only for MPNST in NF1 patients in the US only with a market penetration rate of 25%. Furthermore, by addressing other NF1 related malignancies we will increase this revenue. We are a very strong team with diverse scientific, medical, business and life science entrepreneurs from Texas Medical Center, the world largest medical center.
More information

Advisors

Guillermo Vela
Admin
Guillermo Vela CEO at Nebulab.io. Techstars Cloud alumnus. Former Johns Hopkins brain cancer researcher.